Strongyloidiasis: A review of the evidence for Australian practitioners

Australian Journal of Rural Health

Volumn 13, Issue 4, 2005, Pages 247-254

  Johnston, Fay H ^a,b   Morris, Peter S ^b   Speare, Richard ^e   McCarthy, James ^f   Currie, Bart ^b,d   Ewald, Dan ^d   Page, Wendy ^c   Dempsey, Karen ^e,g  

^a CHARLES DARWIN UNIVERSITY   (Australia)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^c Miwatj Health Aboriginal Corporation   (Australia)

^d FLINDERS UNIVERSITY   (Australia)

^e JAMES COOK UNIVERSITY   (Australia)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g The Australian National University   (Australia)

Author keywords

Aboriginal health; Australia Strongyloides stercoralis; Diagnosis; Public health; Treatment

Indexed keywords

ALBENDAZOLE; ANTHELMINTIC AGENT; IVERMECTIN; PYRVINIUM EMBONATE; TIABENDAZOLE;

ABDOMINAL DISTENSION; ABORIGINE; AUSTRALIA; CLINICAL FEATURE; CLINICAL TRIAL; COCHRANE LIBRARY; COMMUNITY CARE; COUGHING; DATA ANALYSIS; DEATH; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVIDENCE BASED MEDICINE; FECES ANALYSIS; FECES CULTURE; GENERAL PRACTITIONER; HEALTH PROGRAM; HUMAN; IMMUNE DEFICIENCY; LARVA MIGRANS; MEDICAL RESEARCH; MEDLINE; META ANALYSIS; MICROSCOPY; PATIENT CARE; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PRURITUS; PUBLIC HEALTH SERVICE; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEROLOGY; STRONGYLOIDES; STRONGYLOIDIASIS; SYMPTOM; SYSTEMATIC REVIEW; URTICARIA;

ALBENDAZOLE; ANIMALS; ANTHELMINTICS; ANTIGENS, HELMINTH; CHILD; COMMUNICABLE DISEASE CONTROL; EVIDENCE-BASED MEDICINE; FECES; HUMANS; IVERMECTIN; NORTHERN TERRITORY; PREVALENCE; STRONGYLOIDES; STRONGYLOIDIASIS; TREATMENT OUTCOME;

EID: 23744452734     PISSN: 10385282     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1584.2005.00710.x     Document Type: Review

References (52)

1. Grove DI. Human strongyloidiasis (Review). Advances in Parasitology 1996; 38: 251-309.
2. De Silva S, Saykao P, Kelly H et al. Chronic Strongyloides stercoralis infection in Laotian immigrants and refugees 7-20 years after resettlement in Australia. Epidemiological Infection 2002 (Jun); 128 (3): 439-444.
3. Looke DF, Robson J. Infections in the returned traveller. The Medical Journal of Australia 2002 (Aug 19); 177 (4): 212-219.
4. Prociv P. Gastrointestinal worm infections. The prevalence and treatment in Australia. Australian Family Physician 2001 (Aug); 30 (8): 755-761.
5. Kukuruzovic RH, Robins Browne RM, Anstey N, Brewster DR. Enteric pathogens, intestinal permeability and nitric oxide production in childhood diarrheal diseases. Paediatric Infectious Disease Journal 2002 (Aug); 21 (8): 730-739.
6. Barnes GL, Uren E, Stevens KB, Bishop RF. Etiology of acute gastroenteritis in hospitalized children in Melbourne, Australia, from April 1980 to March 1993 Journal of Clinical Microbiology 1998 (Jan); 36 (1): 133-138.
7. Meloni BP, Thompson RC, Hopkins RM, Reynoldson JA, Grcey M. The prevalence of Giardia and other intestinal parasites in children, dogs and cats from aboriginal communties in the Kimberley. The Medical Journal of Australia 1993 (Feb 1); 158 (3): 157-159.
8. Prociv P, Luke R. Observations on strongyloidiasis in Queensland aboriginal communities. The Medical Journal of Australia 1993 (Feb 1); 158 (3): 160-163.
9. Aland K, Prociv P, Currie B, Jones H. Worm Project at Galiwin'ku. Working Together. 1996. Vol. 6, Issue 6, p. 10. See also conference proceedings available at: http://www.sph.uq.edu.au/ACITHN/Conf97/papers97/indigenoushealth.htm
10. Flannery G, White N. Immunological parameters in northeast Arnhem Land Aborigines: consequences of changing settlement and lifestyles. In: Schell LM, Smith MT, Bilsborogh A, eds. Urban Ecology and Health in the Third World. Cambridge: Cambridge University Press, 1993; 202-220.
11. Braunwald E, Fauci AF, Kasper DL, Hauser SL, Longo DL, Jameson JL. Harrison's Principles of Internal Medicine, 15th edn. New York: McGraw-Hill, 2001.
12. Marti H, Haji HJ, Savioli L et al. A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children. The American Journal of Tropical Medical Hygiene 1996 (Nov); 55 (5): 477-481.
13. Siddiqui AA, Berk SL. Diagnosis of Strongyloides stercoralis infection. Clinical Infection and Disease 2001 (Oct 1); 33 (7): 1040-1047.
14. Fisher D, McCarry F, Currie B. Strongyloidiasis in the Northern Territory. 'Under-recognised and under-treated?' The Medical Journal of Australia 1993; 159: 88-90.
15. Dickson R, Awasthi S, Williamson P, Demelweek C, Garner P. Effects of treatment for intestinal helminth infection on growth and cognitive performance in children: systematic review of randomised trials. British Medical Journal 2000; 320: 1697-1701.
16. Stephenson LS, Latham MC, Ottesen EA. Malnutrition and parasitic helminth infections. Parasitology 2000; 121 (Suppl.): S23-S38.
17. Walker AC, Blake G, Downing D et al. A syndrome of partial intestinal obstruction due to Strongyloides stercoralis. The Medical Journal of Australia 1976; 6: 47-48. Special supplement on Aboriginal Health.
18. Lui LX, Weller PF. Strongyloidiasis and other intestinal nematode infections. Infectious Disease Clinics of North America 1993; 7: 655-682.
19. Mak DB. Recurrent bacterial meningitis associated with strongyloides hyperinfection (Letter). The Medical Journal of Australia 1993; 159: 354.
20. Lim L, Biggs B. Fatal disseminated strongyloidiasis in a previously treated patient. The Medical Journal of Australia 2001; 174: 355-356.
21. Davis JA, Curne BJ, Fisher DA et al. Prevention of opportunistic infections in immunosuppressed patients in the tropical Top End of the Northern Territory. Communicable Diseases Intelligence 2003 (Dec); 27 (4): 526-532.
22. Cruz T, Reboucas G, Rocha H. Fatal strongyloidiasis in patients receiving corticosteroids. The New England Journal Medicine 1996 (Nov); 275 (20): 1036-1039.
23. Uparanukraw P, Phongsri S, Morakote N. Fluctuation of larval excretion in Strongyloides stercoralis infection. American Journal of Tropical Medical Hygiene 1999; 60: 967-973.
24. Rawlins SC, Terry SI, Chen WN. Some laboratory, epidemiological and clinical features of Strongyloides stercoralis infection in a focus of low endemicity. West Indies Medical Journal 1983; 32: 212-218.
25. Salazar SA, Gutierrez C, Berk SL. Value of the agar plate method for the diagnosis of intestinal strongyloidiasis. Diagnostic Microbiology and Infectious Disease 1995 (Dec); 23 (4): 141-145.
26. Koga K, Kasuya S, Khamboonruang C et al. An evaluation of the agar plate method for the detection of Strongyloides stercoralis in northern Thailand. Journal of Tropical Medical Hygiene 1990 (June); 93 (3): 183-188.
27. Pelletier LL, Baker CB, Gam AA, Nutman TB, Neva FA. Diagnosis and evaluation of treatment of chronic strongyloidiasis in ex-prisoners of war. Journal of Infectious Diseases 1988 (Mar); 157 (3): 573-576.
28. Dreyer G, Fernandes-Silva E, Alves S, Rocha A, Albuquerque R, Addiss D. Patterns of detection of Strongyloides stercoralis in stool specimens: implications for diagnosis and clinical trials. Journal of Clinical Microbiology 1996; 34: 2569-2571.
29. Bailey JW. A serological test for the diagnosis of Strongyloides antibody in ex-Far East prisoners of war. Annals of Tropical Medicine and Parasitology 1989; 83: 241-247.
30. Lynch NR, Wilkes LK, Hodgen AN, Turner KJ. Specificity of Toxocara Elisa in tropical populations. Parasite Immunology 1988; 10: 323-337.
31. Sampson IA, Grove DI. Strongyloidiasis is endemic in another Australian population group: indochinese immigrants. The Medical Journal of Australia 1987; 146: 580-582.
32. Genta RM. Predictive value of an enzyme-linked immunosorbent assay (ELISA) for the serodiagnosis of strongyloidiasis. American Journal of Clinical Pathology 1988; 89: 391-394.
33. Gam AA, Neva FA, Krotoski WA. Comparative sensitivity and specificity of ELISA and IHA for serodiagnosis of strongyloidiasis with larval antigens. American Journal of Tropical Medical Hygiene 1987 (Jul); 37 (1): 157-161.
34. Lijmer JG, Mol BW, Heisterkamp S et al. Empirical evidence of design related bias in studies of diagnostic tests. Journal of the American Medical Association 2000 (Apr 19); 283 (15): 1963.
35. Sackett DL, Haynes RB. Evidence base of clinical diagnosis: the architecture of diagnostic research. British Medical Journal 2002; 324: 539-541.
36. Loutfy MR, Wilson M, Keystone JS, Kain KC. Serology and eosinophil count in the diagnosis and management of strongyloidiasis in a non-endemic area. American Journal of Tropical Medical Hygiene 2002 (Jun); 66 (6): 749-752.
37. Kobayashi J, Sato Y, Toma H, Takara M, Shiroma Y. Application of enzyme immunoassay for postchemotherapy evaluation of human strongyloidiasis. Diagnostic Microbiology and Infectious Disease 1994 (Jan); 18: 19-23.
38. Schaffel R, Nucci M, Carvalho E et al. The value of an immunoenzymatic test (enzyme-linked immunosorbent assay) for the diagnosis of strongyloidiasis in patients immunosuppressed by hematologic malignancies. American Journal of Tropical Medicine and Hygiene 2001; 65: 346-350.
39. Gyorkos TW, Genta RM, Viens P, MacLean JD. Seroepidemiology of Strongyloides infection in the Southeast Asian refugee population in Canada. American Journal of Epidemiology 1990 (Aug); 132 (2): 257-264.
40. Pene P, Mojon M, Garin JP, Coulaud JP, Rossignol JF. Albendazole: a new broad spectrum anthelmintic. Double-blind multicenter clinical trial. American Journal of Tropical Medical Hygiene 1982; 31: 263-266.
41. Rossignol JF, Maisonneuve H. Albendazole: placebo-controlled study in 870 patients with intestinal helminthiasis. Transactions of the Royal Society of Tropical Medical and Hygiene 1983; 77: 707-711.
42. Adenusi AA, Okel AO, Adenusi AO. Comparison of ivermectin and thiabendazole in the treatment of uncomplicated human Strongyloides stercoralis infection. African Journal of Biotechnology 2003; 2: 465-469.
43. Toma H, Sato Y, Shiroma Y, Kobayashi J, Shimabukuro I, Takara M. Comparative studies on the efficacy of three anthelminthics on treatment of human strongyloidiasis in Okinawa. Japan Southeast Asian Journal of Tropical Medical Public Health 2000 (Mar); 31 (1): 147-151.
44. Datry A, Hilmarsdottir I, Mayorga-Sagastume R et al. Treatment of Strongyloides stercoralis infection with ivermectin compared with albendazole: results of an open study of 60 cases. Transactions of the Royal Society of Tropical Medical and Hygiene 1994 (May-Jun); 88 (3): 344-345.
45. Gann PH, Neva FA, Gam AA. A randomized trial of single- and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis. The Journal of Infectious Disease 1994 (May); 169 (5): 1076-1079.
46. Therapeutic Guidelines; Antibiotic. Therapeutic Guidelines Ltd. Available from URL: http://www.tg.com.au
47. CARPA Standard Treatment Manual, 4th edn. Alice Springs: Central Australian Rural Practitioners Association, 2003.
48. Speare R, White S. Strongyloidiasis - a social determinant of health? Outback Flyer 2001 (Nov/Dec); 50: 4-5.
49. Allen HE, Crompton DW, de Silva N, LoVerde PT, Olds GR. New policies for using anthelmintics in high risk groups. Trends in Parasitology 2002; 18: 381-382.
50. Conway DJ, Lindo JF, Robinson RD, Bundy DAP. Towards effective control of Strongyloides stercoralis. Parasitology Today 1995; 11: 421-424.
51. McCarthy JS, Garrow SC. Parasite elimination programs: at home and away. The Medical Journal of Australia 2002 (May 20); 176 (10): 456-457.
52. Toma H, Shimabukura I, Kobayashi J, Tasaki T, Takara M, Sato Y. Community control studies on Strongyloides infection in a model island of Okinawa, Japan. The Southeast Asian Journal of Tropical Medicine and Public Health 2000 (Jun); 31 (2): 383-387.